Moderna Partners With Mexico for Local Production of 10 Million Vaccine Doses
Moderna has signed a long-term strategic agreement with the Mexican government to transfer mRNA manufacturing technology to Laboratorios Liomont for local COVID-19 vaccine production, targeting up to 10 million doses for the 2025–2026 campaign. The deal also establishes joint R&D programs and strengthens Mexico’s pandemic preparedness framework.
1. Strategic Agreement Details
Moderna and the Mexican government executed a Memorandum of Understanding under "Plan Mexico" to build a domestic mRNA vaccine ecosystem. The pact outlines technology transfer, knowledge sharing and support for regulatory approvals to foster local manufacturing capabilities.
2. Technology Transfer and Production Targets
The agreement commits to transferring mRNA vaccine technology to Laboratorios Liomont, enabling local production of Moderna’s COVID-19 vaccine. The parties aim to supply up to 10 million doses for Mexico’s 2025–2026 vaccination campaign.
3. R&D and Preparedness Collaboration
Beyond manufacturing, the partners will launch joint clinical research initiatives focused on Mexico’s health priorities. The collaboration is designed to bolster the country’s pandemic preparedness by integrating local research, development and regulatory frameworks.
4. Implications for FBT
Moderna ranks among the top five holdings in the biotechnology index tracked by FBT. Successful execution and dose deliveries could enhance Moderna’s revenue outlook and, in turn, support FBT’s net asset value through increased sector exposure.